RMS driven by the fusion protein PAX3-FOXO1, or less commonly PAX7-FOXO1, is well established to be associated with a worse prognosis as compared to fusion-negative RMS tumors, due to aggressive tumor behavior and higher risk of recurrence and dissemination2. Here, PAX3 is linked to neoplasm.